Back to top
more

Esperion Therapeutics (ESPR)

(Delayed Data from NSDQ)

$1.90 USD

1.90
4,197,225

-0.09 (-4.52%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $1.93 +0.03 (1.58%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Esperion (ESPR) to Expand Nilemdo and Nustendi Label in Europe

by Zacks Equity Research

Esperion (ESPR) files type II(a) variation application for expanded use of Nilemdo and Nustendi in Europe to reduce cardiovascular risk.

Why Is Esperion Therapeutics (ESPR) Down 6.9% Since Last Earnings Report?

by Zacks Equity Research

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Esperion (ESPR) Q1 Earnings Miss Estimates, Sales Beat, Stock Up

by Zacks Equity Research

Esperion (ESPR) reports mixed first-quarter 2023 results, wherein earnings miss and revenues beat estimates. The stock of the company surges 5% on Tuesday. The company maintains 2023 guidance.

Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -21.54% and 15.71%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Stevanato Group (STVN) Q1 Earnings Lag Estimates

by Zacks Equity Research

Stevanato (STVN) delivered earnings and revenue surprises of -7.69% and 1.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Esperion Therapeutics (ESPR) Down 74.3% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Esperion (ESPR) Plummets 54% Over Milestone Payment Row

by Zacks Equity Research

An SEC filing by Esperion (ESPR) reveals that partner Daiichi Sankyo disagrees with the company's assessment that cardiovascular outcome CLEAR study data would support milestone payments.

Esperion Therapeutics (ESPR) Down 24% in a Week: Here's Why

by Zacks Equity Research

Shares of Esperion Therapeutics (ESPR) fell last week as the company's cardiovascular outcome CLEAR study results failed to meet investor expectations.

Esperion (ESPR) Q4 Loss Narrows, Revenues Miss, Stock Down

by Zacks Equity Research

Esperion Therapeutics (ESPR) reports mixed fourth-quarter results, beating earnings estimates but missing the same on sales.

Esperion Therapeutics (ESPR) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 12.64% and 5.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

PTC Therapeutics (PTCT) Soars 5.8%: Is Further Upside Left in the Stock?

by Zacks Equity Research

PTC Therapeutics (PTCT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Has CTI BioPharma (CTIC) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how CTI BioPharma (CTIC) and Esperion Therapeutics (ESPR) have performed compared to their sector so far this year.

Esperion (ESPR) Reports Positive Data From CLEAR Study

by Zacks Equity Research

Esperion (ESPR) announces positive data from the CLEAR Outcomes study, which further strengthens the clinical evidence supporting the role of bempedoic acid for patients and will boost the growth potential of the drug.

Is Esperion Therapeutics (ESPR) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Esperion Therapeutics (ESPR) and TransMedics (TMDX) have performed compared to their sector so far this year.

Why Is Esperion Therapeutics (ESPR) Down 16.7% Since Last Earnings Report?

by Zacks Equity Research

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Xeris (XERS), Horizon to Develop Ready-to-Use Teprotumumab

by Zacks Equity Research

Xeris Biopharma (XERS) enters into a research collaboration with Horizon Therapeutics to develop a ready-to-use variant of teprotumumab to treat thyroid eye disease.

Jazz Pharma's (JAZZ) Gets FDA Nod for Rylaze's New Dosing Option

by Zacks Equity Research

Jazz Pharma (JAZZ) gets FDA approval for an MWF intramuscular (IM) dosing schedule for Rylaze to treat acute lymphoblastic leukemia or lymphoblastic lymphoma with hypersensitivity to asparaginase.

InMed (INM) Gets Grant to Begin Neurodegenerative Diseases Program

by Zacks Equity Research

InMed Pharmaceuticals (INM) surges on receiving research grant funding from the Natural Sciences and Engineering Research Council of Canada (NSERC) to investigate its cannabinoid drug candidates.

ImmunoGen (IMGN) Gets Accelerated FDA Approval for Ovarian Cancer Drug

by Zacks Equity Research

ImmunoGen (IMGN) receives accelerated FDA approval for its lead drug mirvetuximab soravtansine-gynx, to be marketed as Elahere. The drug will treat adults with ovarian cancer.

FDA Accepts Amneal's (AMRX) Parkinson's Candidate NDA For Review

by Zacks Equity Research

Amneal Pharmaceuticals' (AMRX) shares rise after the company announces that its Parkinson's candidate IPX203 NDA has been accepted for review by the FDA.

Catalyst Pharmaceuticals (CPRX) to Post Q3 Earnings: What's Up?

by Zacks Equity Research

On Catalyst Pharmaceuticals' (CPRX) third-quarter earnings call, investors will likely focus on the sales performance of Firdapse approved for treating LEMS.

Wall Street Analysts Think Esperion Therapeutics (ESPR) Could Surge 32%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at a 32.5% upside potential for Esperion Therapeutics (ESPR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Has UnitedHealth Group (UNH) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how UnitedHealth Group (UNH) and Esperion Therapeutics (ESPR) have performed compared to their sector so far this year.

Esperion (ESPR) Q3 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Esperion Therapeutics (ESPR) reports mixed third-quarter results, beating earnings estimates but missing out on sales.